{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:12:18Z","timestamp":1793923938297,"version":"4.8.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015068","name":"Universidade de Santiago de Compostela","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015068","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Advances in the understanding of atopic dermatitis (AD) pathogenesis have driven the development of innovative systemic therapies targeting key immunologic pathways. This systematic review summarizes current evidence on the impact of biologic agents, Janus kinase (JAK) inhibitors, and other emerging treatments on AD-related biomarkers and their correlation with clinical outcomes. A comprehensive literature search was conducted across PubMed, Embase, Scopus, and Web of Science for studies published between 2014 and 2024. Eighty studies met the inclusion criteria. Dupilumab was the most extensively investigated therapy, followed by tralokinumab, JAK inhibitors, and novel agents such as amlitelimab, stapokibart, and tezepelumab. Across drug classes, consistent reductions in CCL17\/TARC, LDH, and total IgE levels were observed, generally paralleling clinical improvement in EASI and SCORAD scores. Transcriptomic and proteomic analyses revealed normalization of Th2\/Th22 inflammatory signatures and restoration of barrier-related gene expression, while microbiome studies showed a reduction in\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    colonization. Despite these advances, the heterogeneity of study designs and analytical techniques limits the comparability of results. CCL17 and LDH currently represent the most reliable biomarkers associated with disease severity and treatment response, although their limited specificity restricts clinical applicability. Future research should aim to validate integrated biomarker panels combining immunologic, transcriptomic, and microbiomic data to enable precision medicine approaches in atopic dermatitis management.\n                  <\/jats:p>","DOI":"10.1007\/s12016-025-09129-z","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:36:07Z","timestamp":1769675767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel Therapeutic Strategies for Atopic Dermatitis: Biomarker Modulation and Clinical Implications. A Systematic Review"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2171-411X","authenticated-orcid":false,"given":"Noelia","family":"Moreiras-Arias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4647-1508","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Nieto-Fontarigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4738-215X","authenticated-orcid":false,"given":"Francisco Javier","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9682-5311","authenticated-orcid":false,"given":"Daniel","family":"Gonz\u00e1lez-Vilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7100-6652","authenticated-orcid":false,"given":"Carmen","family":"Paredes-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4032-4431","authenticated-orcid":false,"given":"Enma","family":"Combo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8208-0347","authenticated-orcid":false,"given":"Carmen","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9373-7826","authenticated-orcid":false,"given":"\u00c1ngeles","family":"Fl\u00f3rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"9129_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","volume":"405","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM (2025) Atopic dermatitis. Lancet 405:583\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(24)02519-4","journal-title":"Lancet"},{"key":"9129_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361005","volume":"15","author":"M Afshari","year":"2024","unstructured":"Afshari M, Kolackova M, Rosecka M, \u010celakovsk\u00e1 J, Krejsek J (2024) Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches. Front Immunol 15:1361005. https:\/\/doi.org\/10.3389\/fimmu.2024.1361005","journal-title":"Front Immunol"},{"key":"9129_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/exd.13514","volume":"27","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Guttman-Yassky E, Alexis AF (2018) Atopic dermatitis in diverse racial and ethnic groups\u2014variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol 27:340\u2013357. https:\/\/doi.org\/10.1111\/exd.13514","journal-title":"Exp Dermatol"},{"key":"9129_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/pde.14971","volume":"39","author":"HA Ram\u00edrez-Mar\u00edn","year":"2022","unstructured":"Ram\u00edrez-Mar\u00edn HA, Silverberg JI (2022) Differences between pediatric and adult atopic dermatitis. Pediatr Dermatol 39:345\u2013353. https:\/\/doi.org\/10.1111\/pde.14971","journal-title":"Pediatr Dermatol"},{"key":"9129_CR5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","volume":"151","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, Halling A-S, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI (2023) Comorbidities of atopic dermatitis\u2014what does the evidence say? J Allergy Clin Immunol 151:1155\u20131162. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.002","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR6","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jaip.2020.12.007","volume":"9","author":"F Bawany","year":"2021","unstructured":"Bawany F, Northcott CA, Beck LA, Pigeon WR (2021) Sleep disturbances and atopic dermatitis: relationships, methods for assessment, and therapies. J Allergy Clin Immunol Pract 9:1488\u20131500. https:\/\/doi.org\/10.1016\/j.jaip.2020.12.007","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9129_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164639","volume":"11","author":"S Mastraftsi","year":"2022","unstructured":"Mastraftsi S, Vrioni G, Bakakis M, Nicolaidou E, Rigopoulos D, Stratigos A et al (2022) Atopic dermatitis: striving for reliable biomarkers. J Clin Med 11:4639. https:\/\/doi.org\/10.3390\/jcm11164639","journal-title":"J Clin Med"},{"key":"9129_CR8","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D et al (2021) Biomarkers in atopic dermatitis\u2014a review on behalf of the international eczema Council. J Allergy Clin Immunol 147:1174\u20131190e1. https:\/\/doi.org\/10.1016\/j.jaci.2021.01.013","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2023.100175","volume":"3","author":"T Nakahara","year":"2024","unstructured":"Nakahara T, Onozuka D, Nunomura S, Saeki H, Takenaka M, Matsumoto M et al (2024) The ability of biomarkers to assess the severity of atopic dermatitis. Journal of Allergy and Clinical Immunology: Global 3:100175. https:\/\/doi.org\/10.1016\/j.jacig.2023.100175","journal-title":"Journal of Allergy and Clinical Immunology: Global"},{"key":"9129_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","volume":"25","author":"M Croft","year":"2024","unstructured":"Croft M, Esfandiari E, Chong C, Hsu H, Kabashima K, Kricorian G et al (2024) OX40 in the pathogenesis of atopic dermatitis\u2014a new therapeutic target. Am J Clin Dermatol 25:447\u201361. https:\/\/doi.org\/10.1007\/s40257-023-00838-9","journal-title":"Am J Clin Dermatol"},{"key":"9129_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jaci.2024.04.009","volume":"154","author":"C Rothenberg-Lausell","year":"2024","unstructured":"Rothenberg-Lausell C, Bar J, Dahabreh D, Renert-Yuval Y, Del Duca E, Guttman-Yassky E (2024) Biologic and small-molecule therapy for treating moderate to severe atopic dermatitis: mechanistic considerations. J Allergy Clin Immunol 154:20\u201330","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR12","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.3390\/jcm13144001","volume":"13","author":"K Walig\u00f3ra-Dziwak","year":"2024","unstructured":"Walig\u00f3ra-Dziwak K, Da\u0144czak-Pazdrowska A, Jenerowicz D (2024) A comprehensive review of biologics in phase III and IV clinical trials for atopic dermatitis. J Clin Med 13:4001. https:\/\/doi.org\/10.3390\/jcm13144001","journal-title":"J Clin Med"},{"key":"9129_CR13","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R et al (2020) Chapter 7: systematic reviews of etiology and risk. In: Aromataris E, Munn Z (eds) JBI manual for evidence synthesis. JBI, North Adelaide, Australia","DOI":"10.46658\/JBIRM-17-06"},{"key":"9129_CR14","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"9129_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, Graham NM, Bieber T, Rocklin R et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1314768","journal-title":"N Engl J Med"},{"key":"9129_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, Su\u00e1rez-Fari\u00f1as M, Ardeleanu M, Esaki H et al (2019) Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 143:155\u201372. https:\/\/doi.org\/10.1016\/j.jaci.2018.08.022","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1684\/ejd.2019.3661","volume":"29","author":"TH Huang","year":"2019","unstructured":"Huang TH, Chen Y-C, Lin S-Y, Chiu S-H, Yang T-T, Chiu L-W et al (2019) Treatment of atopic dermatitis with dupilumab in Taiwan: dynamic changes of IgE levels as a potential response biomarker. Eur J Dermatol 29:658\u20139. https:\/\/doi.org\/10.1684\/ejd.2019.3661","journal-title":"Eur J Dermatol"},{"key":"9129_CR18","doi-asserted-by":"publisher","unstructured":"Olesen CM, Holm JG, N\u00f8rreslet LB, Serup JV, Thomsen SF, Agner T (2019) Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol 33:1562\u20131568. https:\/\/doi.org\/10.1111\/jdv.15609","DOI":"10.1111\/jdv.15609"},{"key":"9129_CR19","doi-asserted-by":"publisher","unstructured":"Ari\u00ebns LFM, Van Der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T et al (2020) Dupilumab is very effective in a large cohort of difficult-to\u2010treat adult atopic dermatitis patients: first clinical and biomarker results from the bioday registry. Allergy 75:116\u2013126.https:\/\/doi.org\/10.1111\/all.14080","DOI":"10.1111\/all.14080"},{"key":"9129_CR20","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1111\/all.14492","volume":"75","author":"DS Bakker","year":"2020","unstructured":"Bakker DS, Ariens LFM, Giovannone B, Hijnen D, Delemarre EM, Knol E et al (2020) EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. Allergy 75:3287\u20139. https:\/\/doi.org\/10.1111\/all.14492","journal-title":"Allergy"},{"key":"9129_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jid.2019.05.024","volume":"140","author":"C Callewaert","year":"2020","unstructured":"Callewaert C, Nakatsuji T, Knight R, Kosciolek T, Vrbanac A, Kotol P et al (2020) IL-4R\u03b1 blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J Invest Dermatol 140:191-202.e7. https:\/\/doi.org\/10.1016\/j.jid.2019.05.024","journal-title":"J Invest Dermatol"},{"key":"9129_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030791","volume":"9","author":"S Ferrucci","year":"2020","unstructured":"Ferrucci S, Casazza G, Angileri L, Tavecchio S, Germiniasi F, Berti E et al (2020) Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience. J Clin Med 9:791. https:\/\/doi.org\/10.3390\/jcm9030791","journal-title":"J Clin Med"},{"key":"9129_CR23","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/cea.13954","volume":"51","author":"JD Hamilton","year":"2021","unstructured":"Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS et al (2021) Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy 51:915\u201331. https:\/\/doi.org\/10.1111\/cea.13954","journal-title":"Clin Exp Allergy"},{"key":"9129_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01768","volume":"11","author":"H He","year":"2020","unstructured":"He H, Olesen CM, Pavel AB, Clausen M-L, Wu J, Estrada Y et al (2020) Tape-strip proteomic profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers. Front Immunol 11:1768. https:\/\/doi.org\/10.3389\/fimmu.2020.01768","journal-title":"Front Immunol"},{"key":"9129_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061982","volume":"9","author":"DH Jang","year":"2020","unstructured":"Jang DH, Heo SJ, Jung HJ, Park MY, Seo SJ, Ahn J (2020) Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in Korea: efficacy and safety of Dupilumab in real-world practice. J Clin Med 9:1982. https:\/\/doi.org\/10.3390\/jcm9061982","journal-title":"J Clin Med"},{"key":"9129_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bjd.18565","volume":"183","author":"N Katoh","year":"2020","unstructured":"Katoh N, Kataoka Y, Saeki H, Hide M, Kabashima K, Etoh T et al (2020) Efficacy and safety of dupilumab in Japanese adults with moderate-to\u2010severe atopic dermatitis: a subanalysis of three clinical trials. Br J Dermatol 183:39\u201351. https:\/\/doi.org\/10.1111\/bjd.18565","journal-title":"Br J Dermatol"},{"key":"9129_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ijd.15183","volume":"60","author":"T Yamauchi","year":"2021","unstructured":"Yamauchi T, Sasaki S, Lee ES, Tamura T, Seki M, Miwa T et al (2021) Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis. Int J Dermatol 60:190\u20135. https:\/\/doi.org\/10.1111\/ijd.15183","journal-title":"Int J Dermatol"},{"key":"9129_CR28","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.jid.2021.01.022","volume":"141","author":"DS Bakker","year":"2021","unstructured":"Bakker DS, Van Der Wal MM, Heeb LEM, Giovannone B, Asamoah M, Delemarre EM et al (2021) Early and long-term effects of dupilumab treatment on circulating T-cell functions in patients with moderate-to-severe atopic dermatitis. J Invest Dermatol 141:1943-1953.e13. https:\/\/doi.org\/10.1016\/j.jid.2021.01.022","journal-title":"J Invest Dermatol"},{"key":"9129_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.4168\/aair.2021.13.5.733","volume":"13","author":"Y Lee","year":"2021","unstructured":"Lee Y, Kim M-E, Nahm D-H (2021) Real clinical practice data of monthly dupilumab therapy in adult patients with moderate-to-severe atopic dermatitis: clinical efficacy and predictive markers for a favorable clinical response. Allergy Asthma Immunol Res 13:733. https:\/\/doi.org\/10.4168\/aair.2021.13.5.733","journal-title":"Allergy Asthma Immunol Res"},{"key":"9129_CR30","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1097\/DER.0000000000000764","volume":"32","author":"D Mikhaylov","year":"2021","unstructured":"Mikhaylov D, Del Duca E, Olesen CM, He H, Wu J, Ungar B et al (2021) Transcriptomic profiling of tape-strips from moderate to severe atopic dermatitis patients treated with dupilumab. Dermatitis 32:S71\u201380. https:\/\/doi.org\/10.1097\/DER.0000000000000764","journal-title":"Dermatitis"},{"key":"9129_CR31","doi-asserted-by":"publisher","unstructured":"Mizuno M, Horiguchi G, Teramukai S, Ichiyama S, Ito M, Hoashi T et al (2021) Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab. Aust J Dermatology 62. https:\/\/doi.org\/10.1111\/ajd.13719","DOI":"10.1111\/ajd.13719"},{"key":"9129_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaci.2020.06.012","volume":"147","author":"L M\u00f6bus","year":"2021","unstructured":"M\u00f6bus L, Rodriguez E, Harder I, St\u00f6lzl D, Boraczynski N, Gerdes S et al (2021) Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J Allergy Clin Immunol 147:213\u201323. https:\/\/doi.org\/10.1016\/j.jaci.2020.06.012","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR33","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.jaci.2020.11.022","volume":"147","author":"L M\u00f6bus","year":"2021","unstructured":"M\u00f6bus L, Rodriguez E, Harder I, Schwarz A, Wehkamp U, St\u00f6lzl D et al (2021) Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis. J Allergy Clin Immunol 147:1959-1965.e2. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.022","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5021\/ad.21.321","volume":"34","author":"Y Bae","year":"2022","unstructured":"Bae Y, Kim S-J (2022) Serum ceruloplasmin as a potential clinical biomarker in atopic dermatitis. Ann Dermatol 34:245. https:\/\/doi.org\/10.5021\/ad.21.321","journal-title":"Ann Dermatol"},{"key":"9129_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13887","volume":"33","author":"E Kamphuis","year":"2022","unstructured":"Kamphuis E, Boesjes CM, Loman L, Bakker DS, Poelhekken M, Zuithoff NPA et al (2022) Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry. Pediatr Allergy Immunol 33:e13887. https:\/\/doi.org\/10.1111\/pai.13887","journal-title":"Pediatr Allergy Immunol"},{"key":"9129_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/cia2.12282","volume":"6","author":"K Kita","year":"2023","unstructured":"Kita K, Imai Y, Nagai M, Natsuaki M, Kanazawa N (2023) Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis. J Cutan Imm Allergy 6:100\u2013101. https:\/\/doi.org\/10.1002\/cia2.12282","journal-title":"J Cutan Imm Allergy"},{"key":"9129_CR37","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.3390\/jcm11216255","volume":"11","author":"S-H Lee","year":"2022","unstructured":"Lee S-H, Bae Y, Park Y-L (2022) Clinical implication of serum adiponectin levels in adult patients. JCM 11:6255. https:\/\/doi.org\/10.3390\/jcm11216255","journal-title":"JCM"},{"key":"9129_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.18176\/jiaci.0641","volume":"32","author":"E Nettis","year":"2022","unstructured":"Nettis E, Ferrucci S, Ortoncelli M, Pellacani G, Foti C, Di Leo E et al (2022) Use of dupilumab in 543 adult patients with moderate-to-severe atopic dermatitis: a multicenter, retrospective study. J Investig Allergol Clin Immunol 32:124\u201332. https:\/\/doi.org\/10.18176\/jiaci.0641","journal-title":"J Investig Allergol Clin Immunol"},{"key":"9129_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40272-022-00553-8","volume":"25","author":"AS Paller","year":"2023","unstructured":"Paller AS, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Gonzalez ME et al (2023a) Laboratory safety from a randomized 16-week phase III study of dupilumab in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Pediatr Drugs 25:67\u201377. https:\/\/doi.org\/10.1007\/s40272-022-00553-8","journal-title":"Pediatr Drugs"},{"key":"9129_CR40","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1111\/all.15439","volume":"77","author":"LS Spekhorst","year":"2022","unstructured":"Spekhorst LS, Bakker D, Drylewicz J, Rispens T, Loeff F, Boesjes CM et al (2022) Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Allergy 77:3398\u2013407. https:\/\/doi.org\/10.1111\/all.15439","journal-title":"Allergy"},{"key":"9129_CR41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5582\/ddt.2022.01046","volume":"16","author":"E Tosuji","year":"2022","unstructured":"Tosuji E, Inaba Y, Muraoka K, Kunimoto K, Kaminaka C, Yamamoto Y et al (2022) The clinical significance of dupilumab-induced blood eosinophil elevation in Japanese patients with atopic dermatitis. Drug Discoveries & Therapeutics 16:164\u20138. https:\/\/doi.org\/10.5582\/ddt.2022.01046","journal-title":"Drug Discoveries & Therapeutics"},{"key":"9129_CR42","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/cea.14147","volume":"52","author":"C Varandas","year":"2022","unstructured":"Varandas C, Pereira-Santos MC, Neto M, Sousa AE, Lopes A, Silva SL (2022) Serum IL\u201022 binding protein as a marker for atopic dermatitis activity and response to dupilumab treatment. Clin Exp Allergy 52:820\u2013823. https:\/\/doi.org\/10.1111\/cea.14147","journal-title":"Clin Exp Allergy"},{"key":"9129_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1002536","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wen X, Hou Y, Yang Y, Song W, Zeng Y et al (2022) Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab. Front Immunol 13:1002536. https:\/\/doi.org\/10.3389\/fimmu.2022.1002536","journal-title":"Front Immunol"},{"key":"9129_CR44","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/JD9.0000000000000264","volume":"5","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Wu L-M, Lu Q-J, Gao X-H, Zhu X-H, Yao X et al (2022) Laboratory safety of dupilumab, and its effect on inflammatory biomarkers, in Chinese adults with moderate-to-severe atopic dermatitis: an analysis of a randomized, double-blind phase III study. Int J Dermatol Venereol 5:218\u201325. https:\/\/doi.org\/10.1097\/JD9.0000000000000264","journal-title":"Int J Dermatol Venereol"},{"key":"9129_CR45","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s13555-023-00918-y","volume":"13","author":"J \u010celakovsk\u00e1","year":"2023","unstructured":"\u010celakovsk\u00e1 J, \u010cerm\u00e1kov\u00e1 E, Boudkov\u00e1 P, Andr\u00fds C, Krejsek J (2023) Evaluation of leukocytes, b and t lymphocytes, and expression of CD200 and CD23 on b lymphocytes in patients with atopic dermatitis on dupilumab therapy\u2014pilot study. Dermatol Ther (Heidelb) 13:1171\u201392","journal-title":"Dermatol Ther (Heidelb)"},{"key":"9129_CR46","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s13555-023-00922-2","volume":"13","author":"J \u010celakovsk\u00e1","year":"2023","unstructured":"\u010celakovsk\u00e1 J, \u010cerm\u00e1kov\u00e1 E, Boudkov\u00e1 P, Andr\u00fds C, Krejsek J (2023) The association between eosinophils (CD16\u2009+\u2009eosinophils), basophils (CD203\u2009+\u2009basophils), and CD23 b lymphocytes in patients with atopic dermatitis on dupilumab therapy: pilot study. Dermatol Ther 13:1193\u2013210. https:\/\/doi.org\/10.1007\/s13555-023-00922-2","journal-title":"Dermatol Ther"},{"key":"9129_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cells12020239","volume":"12","author":"R Kishi","year":"2023","unstructured":"Kishi R, Toyama S, Tominaga M, Kamata Y, Komiya E, Kaneko T et al (2023) Effects of dupilumab on itch-related events in atopic dermatitis: implications for assessing treatment efficacy in clinical practice. Cells 12:239. https:\/\/doi.org\/10.3390\/cells12020239","journal-title":"Cells"},{"key":"9129_CR48","doi-asserted-by":"publisher","first-page":"adv5320","DOI":"10.2340\/actadv.v103.5320","volume":"103","author":"G-W Lee","year":"2023","unstructured":"Lee G-W, Kim K, Kim S-J, Shin K, Kim H, Ko H-C et al (2023) Therapeutic effect of dupilumab on systemic and vascular inflammation in adults with severe atopic dermatitis: feasibility study using 18F-fluorodeoxyglucose positron emission tomography-computed tomography. Acta Derm Venereol 103:adv5320. https:\/\/doi.org\/10.2340\/actadv.v103.5320","journal-title":"Acta Derm Venereol"},{"key":"9129_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/9013756","volume":"2023","author":"S Miyamoto","year":"2023","unstructured":"Miyamoto S, Imai Y, Matsutani M, Nagai M, Yamanishi K, Kanazawa N et al (2023) Exploration of metabolite biomarkers to predict the efficacy of dupilumab treatment for atopic dermatitis. Dis Markers 2023:1\u20138. https:\/\/doi.org\/10.1155\/2023\/9013756","journal-title":"Dis Markers"},{"key":"9129_CR50","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1089\/derm.2023.0176","volume":"35","author":"T Montero-Vilchez","year":"2024","unstructured":"Montero-Vilchez T, Rodriguez-Pozo J-A, Cuenca-Barrales C, Sanabria-de-la-Torre R, Torres-de-Pinedo J-M, Arias-Santiago S (2024) Stratum corneum hydration as a potential marker of response to dupilumab in atopic dermatitis\u00ae: a prospective observational study. Dermatitis 35:250\u2013257. https:\/\/doi.org\/10.1089\/derm.2023.0176","journal-title":"Dermatitis"},{"key":"9129_CR51","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cea.14267","volume":"53","author":"T Nakahara","year":"2023","unstructured":"Nakahara T, Izuhara K, Onozuka D, Saeki H, Nunomura S, Takenaka M et al (2023) Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B-PAD study). Clin Exp Allergy 53:233\u20138. https:\/\/doi.org\/10.1111\/cea.14267","journal-title":"Clin Exp Allergy"},{"key":"9129_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamadermatol.2022.6192","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Lockshin B, Irvine AD et al (2023b) Efficacy and safety of dupilumab in patients with erythrodermic atopic dermatitis: a post hoc analysis of 6 randomized clinical trials. JAMA Dermatol 159:255. https:\/\/doi.org\/10.1001\/jamadermatol.2022.6192","journal-title":"JAMA Dermatol"},{"key":"9129_CR53","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2147\/JAA.S433515","volume":"16","author":"M Rossi","year":"2023","unstructured":"Rossi M, Bettolini L, Artelli G, Fragh\u00ec A, Tomasi C, Calzavara-Pinton P (2023) Dupilumab treatment efficacy and impact on clinical scores, serum biomarkers, and itch in adult patients with atopic dermatitis: a retrospective analysis. J Asthma Allergy 16:1233\u201340. https:\/\/doi.org\/10.2147\/JAA.S433515","journal-title":"J Asthma Allergy"},{"key":"9129_CR54","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40257-022-00754-4","volume":"24","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Lynde CW, Abuabara K, Patruno C, De Benedetto A, Zhang H et al (2023) Efficacy and safety of dupilumab maintained in adults\u2009\u2265\u200960 years of age with moderate-to-severe atopic dermatitis: analysis of pooled data from four randomized clinical trials. Am J Clin Dermatol 24:469\u201383. https:\/\/doi.org\/10.1007\/s40257-022-00754-4","journal-title":"Am J Clin Dermatol"},{"key":"9129_CR55","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaci.2023.05.026","volume":"152","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Schlievert PM, Yoshida T, Lussier S, Boguniewicz M, Hata T et al (2023) Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment. J Allergy Clin Immunol 152:1179\u201395. https:\/\/doi.org\/10.1016\/j.jaci.2023.05.026","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR56","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jaad.2022.12.052","volume":"88","author":"K Singh","year":"2023","unstructured":"Singh K, Valido K, Swallow M, Okifo KO, Wang A, Cohen JM et al (2023) Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis. J Am Acad Dermatol 88:1094\u2013100. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.052","journal-title":"J Am Acad Dermatol"},{"key":"9129_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1160710","volume":"14","author":"A Wang","year":"2023","unstructured":"Wang A, Zhou Y, Luo Y, Gao Y, Chen J, Li W et al (2023) High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis. Front Immunol 14:1160710. https:\/\/doi.org\/10.3389\/fimmu.2023.1160710","journal-title":"Front Immunol"},{"key":"9129_CR58","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/bjd\/ljad032","volume":"188","author":"Y Wu","year":"2023","unstructured":"Wu Y, Gu C, Wang S, Yin H, Qiu Z, Luo Y et al (2023) Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab. Br J Dermatol 188:649\u201360. https:\/\/doi.org\/10.1093\/bjd\/ljad032","journal-title":"Br J Dermatol"},{"key":"9129_CR59","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2024.08.005","volume":"155","author":"LA Beck","year":"2025","unstructured":"Beck LA, Muraro A, Boguniewicz M, Chen Z, Zahn J, Rodr\u00edguez Marco A (2025) Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 155:135\u2013143. https:\/\/doi.org\/10.1016\/j.jaci.2024.08.005","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112023","volume":"132","author":"J \u010celakovsk\u00e1","year":"2024","unstructured":"\u010celakovsk\u00e1 J, \u010cerm\u00e1kova E, Boudkov\u00e1 P, Andr\u00fds C, Krejsek J (2024) The association between expression of CD200 on b lymphocytes and the count of eosinophils and basophils in atopic dermatitis patients with and without dupilumab therapy \u2013 pilot study. Int Immunopharmacol 132:112023. https:\/\/doi.org\/10.1016\/j.intimp.2024.112023","journal-title":"Int Immunopharmacol"},{"key":"9129_CR61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/25785826.2024.2387882","volume":"48","author":"J \u010celakovsk\u00e1","year":"2025","unstructured":"\u010celakovsk\u00e1 J, \u010cerm\u00e1kov\u00e1 E, Boudkov\u00e1 P, And\u00fds C, Krejsek J (2025) Differences in immunological profile in atopic dermatitis patients with and without dupilumab therapy. Immunol Med 48:33\u201346","journal-title":"Immunol Med"},{"key":"9129_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/cea.14585","volume":"55","author":"C Dekkers","year":"2025","unstructured":"Dekkers C, Smits H, St\u00f6lzl D, Spekhorst L, Knol E, Van Wijk F et al (2025a) Type 2 immune-dominant endotype is not associated with increased responsiveness to dupilumab treatment in adult atopic dermatitis patients. Clin Experimental Allergy 55:97\u201399. https:\/\/doi.org\/10.1111\/cea.14585","journal-title":"Clin Experimental Allergy"},{"key":"9129_CR63","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2024.09.017","volume":"155","author":"HM Kenney","year":"2025","unstructured":"Kenney HM, Yoshida T, Berdyshev E, Calatroni A, Gill SR, Simpson EL et al (2025) CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity. J Allergy Clin Immunol 155:479\u201390. https:\/\/doi.org\/10.1016\/j.jaci.2024.09.017","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100317","volume":"3","author":"M Kido-Nakahara","year":"2024","unstructured":"Kido-Nakahara M, Onozuka D, Izuhara K, Saeki H, Nunomura S, Takenaka M et al (2024) Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis. J Allergy Clin Immunol Glob 3:100317. https:\/\/doi.org\/10.1016\/j.jacig.2024.100317","journal-title":"J Allergy Clin Immunol Glob"},{"key":"9129_CR65","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2024.16.6.682","volume":"16","author":"J Kim","year":"2024","unstructured":"Kim J, Boo J, Jang H, Jung YW, Kim J, Zhang K et al (2024) Combined dupilumab and allergen-specific immunotherapy in severe refractory atopic dermatitis. Allergy Asthma Immunol Res 16:682. https:\/\/doi.org\/10.4168\/aair.2024.16.6.682","journal-title":"Allergy Asthma Immunol Res"},{"key":"9129_CR66","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.341","author":"R Lim\u00e3o","year":"2024","unstructured":"Lim\u00e3o R, Br\u00e1s R, Pedro E, Silva SL, Lopes A (2024) Dupilumab in patients with atopic dermatitis: assessing treatment response, clinical features and potential biomarkers in real-life. Eur Ann Allergy Clin Immunol. https:\/\/doi.org\/10.23822\/EurAnnACI.1764-1489.341","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"9129_CR67","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/life14030352","volume":"14","author":"GG Mitroi","year":"2024","unstructured":"Mitroi GG, Ple\u0219ea EL, Mitroi GF, Mitroi MR, Neagoe CD, Iano\u0219i SL (2024) Exploring the potential of IL-4 and IL-13 plasma levels as biomarkers in atopic dermatitis. Life 14:352. https:\/\/doi.org\/10.3390\/life14030352","journal-title":"Life"},{"key":"9129_CR68","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1021\/acs.jproteome.4c00153","volume":"23","author":"F Monedeiro","year":"2024","unstructured":"Monedeiro F, Ehall B, Tiffner K, Eberl A, Svehlikova E, Prietl B et al (2024) Characterization of inflammatory mediators and metabolome in interstitial fluid collected with dermal open flow microperfusion before and at the end of dupilumab treatment in atopic dermatitis. J Proteome Res 23:3496\u2013514. https:\/\/doi.org\/10.1021\/acs.jproteome.4c00153","journal-title":"J Proteome Res"},{"key":"9129_CR69","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/jdv.19911","volume":"38","author":"K Pa\u017eur","year":"2024","unstructured":"Pa\u017eur K, Francuzik W, El-Mahmoud H, Kraft M, Worm M (2024) Proteomic, miRNA and bacterial biomarker patterns in atopic dermatitis patients and their course upon anti\u2010IL\u20104R\u03b1 therapy. Acad Dermatol Venereol 38:1749\u201359. https:\/\/doi.org\/10.1111\/jdv.19911","journal-title":"Acad Dermatol Venereol"},{"key":"9129_CR70","doi-asserted-by":"publisher","DOI":"10.23736\/S2784-8671.23.07630-2","author":"A Raimondo","year":"2024","unstructured":"Raimondo A, Balestrino A, Ligrone L, Lembo S (2024) Dupilumab therapy reduces urinary biopyrrin levels in atopic patients: a new possible biomarker of oxidative status in atopic dermatitis. Ital J Dermatol Venereol. https:\/\/doi.org\/10.23736\/S2784-8671.23.07630-2","journal-title":"Ital J Dermatol Venereol"},{"key":"9129_CR71","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1111\/all.16377","volume":"79","author":"E Scala","year":"2024","unstructured":"Scala E, Madonna S, Abeni D, Cecchi L, Cocuroccia B, Dattolo A et al (2024) A microarray-based IgE \u2010molecular mimicry index ( IgE \u2010 MMI ): a biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis? Allergy 79:3415\u201329. https:\/\/doi.org\/10.1111\/all.16377","journal-title":"Allergy"},{"key":"9129_CR72","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1111\/all.16147","volume":"79","author":"D St\u00f6lzl","year":"2024","unstructured":"St\u00f6lzl D, Sander N, Siegels D, Harder I, Kind B, Fonfara M et al (2024) Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: results of the German TREATkids registry. Allergy 79:2849\u201352. https:\/\/doi.org\/10.1111\/all.16147","journal-title":"Allergy"},{"key":"9129_CR73","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s13555-021-00678-7","volume":"12","author":"R Sidbury","year":"2022","unstructured":"Sidbury R, Alpizar S, Laquer V, Dhawan S, Abramovits W, Loprete L et al (2022) Pharmacokinetics, safety, efficacy, and biomarker profiles during nemolizumab treatment of atopic dermatitis in adolescents. Dermatol Ther (Heidelb) 12:631\u201342. https:\/\/doi.org\/10.1007\/s13555-021-00678-7","journal-title":"Dermatol Ther (Heidelb)"},{"key":"9129_CR74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","volume":"143","author":"A Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K et al (2019) Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb. J Allergy Clin Immunol 143:135\u201341. https:\/\/doi.org\/10.1016\/j.jaci.2018.05.029","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR75","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/all.16414","volume":"80","author":"C Dekkers","year":"2025","unstructured":"Dekkers C, Zuithoff N, Bakker D, Knol E, Wevers A, Touwslager W et al (2025b) Tralokinumab treatment in adult atopic dermatitis patients: 28-week evaluation of clinical effectiveness, safety, serum proteins and total IgE levels. Allergy 80:1060\u20131073. https:\/\/doi.org\/10.1111\/all.16414","journal-title":"Allergy"},{"key":"9129_CR76","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/all.16108","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Kabashima K, Staumont\u2010Salle D, Nahm WK, Pauser S, Da Rosa JC et al (2024a) Targeting IL \u201013 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy 79:1560\u20131572. https:\/\/doi.org\/10.1111\/all.16108","journal-title":"Allergy"},{"key":"9129_CR77","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/bjd\/ljae138","volume":"191","author":"N Sander","year":"2024","unstructured":"Sander N, St\u00f6lzl D, Fonfara M, Hartmann J, Harder I, Suhrkamp I et al (2024) Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis. Br J Dermatol 191:344\u201350. https:\/\/doi.org\/10.1093\/bjd\/ljae138","journal-title":"Br J Dermatol"},{"key":"9129_CR78","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s13555-022-00764-4","volume":"12","author":"MJ Gooderham","year":"2022","unstructured":"Gooderham MJ, Girolomoni G, Moore JO, Silverberg JI, Bissonnette R, Forman S et al (2022) Durability of response to abrocitinib in patients with moderate-to-severe atopic dermatitis after treatment discontinuation in a phase 2b trial. Dermatol Ther 12:2077\u201385. https:\/\/doi.org\/10.1007\/s13555-022-00764-4","journal-title":"Dermatol Ther"},{"key":"9129_CR79","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/all.15969","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Facheris P, Gomez\u2010Arias PJ, Del Duca E, Da Rosa JC, Weidinger S et al (2024b) Effect of abrocitinib on skin biomarkers in patients with moderate\u2010to\u2010severe atopic dermatitis. Allergy 79:1258\u20131270. https:\/\/doi.org\/10.1111\/all.15969","journal-title":"Allergy"},{"key":"9129_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41609-z","volume":"9","author":"RJ Konrad","year":"2019","unstructured":"Konrad RJ, Higgs RE, Rodgers GH, Ming W, Qian Y-W, Bivi N et al (2019) Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay. Sci Rep 9:5211. https:\/\/doi.org\/10.1038\/s41598-019-41609-z","journal-title":"Sci Rep"},{"key":"9129_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/jcia.2024.12455","volume":"7","author":"A Watanabe","year":"2024","unstructured":"Watanabe A, Kamata M, Okada Y, Suzuki S, Ito M, Mizukawa I et al (2024) Real-world effectiveness and safety of baricitinib including its effect on biomarkers and laboratory data in Japanese adult patients with atopic dermatitis: a single-center retrospective study. Journal of Cutaneous Immunology and Allergy 7:12455. https:\/\/doi.org\/10.3389\/jcia.2024.12455","journal-title":"Journal of Cutaneous Immunology and Allergy"},{"key":"9129_CR82","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/1346-8138.16549","volume":"49","author":"T Hagino","year":"2022","unstructured":"Hagino T, Saeki H, Kanda N (2022) The efficacy and safety of Upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol 49:1158\u20131167. https:\/\/doi.org\/10.1111\/1346-8138.16549","journal-title":"J Dermatol"},{"key":"9129_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062201","volume":"12","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N (2023) The eosinophil-to-lymphocyte ratio acts as an indicator for improvement of clinical signs and itch by upadacitinib treatment in atopic dermatitis. J Clin Med 12:2201. https:\/\/doi.org\/10.3390\/jcm12062201","journal-title":"J Clin Med"},{"key":"9129_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111193","volume":"125","author":"L Li","year":"2023","unstructured":"Li L, Wu N, Liu T, Yu G, Wang Y, He T et al (2023) The efficacy and immunological effects of upadacitinib in the treatment of moderate-to-severe Chinese atopic dermatitis patients. Int Immunopharmacol 125:111193. https:\/\/doi.org\/10.1016\/j.intimp.2023.111193","journal-title":"Int Immunopharmacol"},{"key":"9129_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1365544","volume":"15","author":"T Hagino","year":"2024","unstructured":"Hagino T, Hamada R, Yoshida M, Fujimoto E, Saeki H, Kanda N (2024) Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks. Front Immunol 15:1365544. https:\/\/doi.org\/10.3389\/fimmu.2024.1365544","journal-title":"Front Immunol"},{"key":"9129_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/jcia.2024.13404","volume":"7","author":"T Koga","year":"2024","unstructured":"Koga T, Okada K, Shimizu T, Morita E, Itazawa T (2024) Consideration of treatment goals and termination algorithm for adolescent atopic dermatitis using upadacitinib. J Cutan Immunol Allergy 7:13404. https:\/\/doi.org\/10.3389\/jcia.2024.13404","journal-title":"J Cutan Immunol Allergy"},{"key":"9129_CR87","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","volume":"144","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H et al (2019) GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol 144:482-493.e7. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.053","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR88","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bjd.17932","volume":"181","author":"R Bissonnette","year":"2019","unstructured":"Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J et al (2019) The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN 002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to\u2010severe atopic dermatitis: results from a randomized double\u2010blind placebo\u2010controlled study. Br J Dermatol 181:733\u201342. https:\/\/doi.org\/10.1111\/bjd.17932","journal-title":"Br J Dermatol"},{"key":"9129_CR89","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","volume":"144","author":"AB Pavel","year":"2019","unstructured":"Pavel AB, Song T, Kim H-J, Del Duca E, Krueger JG, Dubin C et al (2019) Oral Janus kinase\/SYK Inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. J Allergy Clin Immunol 144:1011\u20131024. https:\/\/doi.org\/10.1016\/j.jaci.2019.07.013","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR90","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","volume":"80","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, Parnes JR, She D, Crouch S, Rees W, Mo M et al (2019) Tezepelumab, an anti\u2013thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol 80:1013\u201321. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.059","journal-title":"J Am Acad Dermatol"},{"key":"9129_CR91","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/cts.13656","volume":"16","author":"J Wang","year":"2023","unstructured":"Wang J, White J, Sansone KJ, Spelman L, Sinclair R, Yang X et al (2023) Rademikibart (CBP -201), a next\u2010generation monoclonal antibody targeting human IL\u20104R\u03b1: two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Clin Transl Sci 16:2614\u201327. https:\/\/doi.org\/10.1111\/cts.13656","journal-title":"Clin Transl Sci"},{"key":"9129_CR92","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s13555-023-01010-1","volume":"13","author":"CJ Wynne","year":"2023","unstructured":"Wynne CJ, Cole A, Lemech C, Wang G, Zhang Y, Chen B et al (2023) Safety, pharmacokinetics and preliminary efficacy of IL4-R\u03b1 monoclonal antibody AK120 in both healthy and atopic dermatitis subjects: a phase I, randomized, two-part, double-blind, placebo-controlled, dose-escalation, first-in-human clinical study. Dermatol Ther (Heidelb) 13:2357\u201373. https:\/\/doi.org\/10.1007\/s13555-023-01010-1","journal-title":"Dermatol Ther (Heidelb)"},{"key":"9129_CR93","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","volume":"155","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Blauvelt A, Papp KA, Reich A, Lee C-H, Worm M et al (2025) Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 155:1264\u201375. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.031","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR94","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1007\/s12325-024-02887-w","volume":"41","author":"L Zhang","year":"2024","unstructured":"Zhang L, Zhang W, Xu Y, Dong L, Sun Y, Jia Y et al (2024) Pharmacokinetics, pharmacodynamics, safety, and tolerability of stapokibart in healthy volunteers and adult subjects with atopic dermatitis. Adv Ther 41:2953\u201365. https:\/\/doi.org\/10.1007\/s12325-024-02887-w","journal-title":"Adv Ther"},{"key":"9129_CR95","doi-asserted-by":"publisher","first-page":"T66","DOI":"10.1016\/j.ad.2023.10.032","volume":"115","author":"JM Carrascosa-Carrillo","year":"2024","unstructured":"Carrascosa-Carrillo JM, Aterido A, Li T, Guill\u00e9n Y, Martinez S, Marsal S et al (2024) [Art\u00edculo traducido]. Hacia Una medicina de precisi\u00f3n En La dermatitis at\u00f3pica mediante El Uso de Enfoques moleculares. Actas Dermosifiliogr 115:T66\u201375. https:\/\/doi.org\/10.1016\/j.ad.2023.10.032","journal-title":"Actas Dermosifiliogr"},{"key":"9129_CR96","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1111\/all.16183","volume":"79","author":"S Nakajima","year":"2024","unstructured":"Nakajima S, Nakamizo S, Nomura T, Ishida Y, Sawada Y, Kabashima K (2024) Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions. Allergy 79:2366\u20132379. https:\/\/doi.org\/10.1111\/all.16183","journal-title":"Allergy"},{"key":"9129_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Krueger JG, Guttman-Yassky E (2019) Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol 143:1\u201311. https:\/\/doi.org\/10.1016\/j.jaci.2018.10.032","journal-title":"J Allergy Clin Immunol"},{"key":"9129_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052684","volume":"23","author":"L Fania","year":"2022","unstructured":"Fania L, Moretta G, Antonelli F, Scala E, Abeni D, Albanesi C et al (2022) Multiple Role s for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets. Int J Mol Sci 23:2684. https:\/\/doi.org\/10.3390\/ijms23052684","journal-title":"Int J Mol Sci"},{"key":"9129_CR99","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jid.2022.10.015","volume":"143","author":"C Grolleau","year":"2023","unstructured":"Grolleau C, Calugareanu A, Demouche S, Nosbaum A, Staumont-Sall\u00e9 D, Aubert H et al (2023) IL-4\/IL-13 inhibitors for atopic dermatitis induce psoriatic rash transcriptionally close to pustular psoriasis. J Invest Dermatol 143:711-721.e7. https:\/\/doi.org\/10.1016\/j.jid.2022.10.015","journal-title":"J Invest Dermatol"},{"key":"9129_CR100","doi-asserted-by":"publisher","unstructured":"Chiei Gallo A, Tavoletti G, Termini D, Avallone G, Barei F, Calzari P et al Phenotypic switch from atopic dermatitis to psoriasis during dupilumab therapy: A Real-Life experience from a tertiary referral center. Int J Dermatol 2025 https:\/\/doi.org\/10.1111\/ijd.70105","DOI":"10.1111\/ijd.70105"},{"key":"9129_CR101","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/ced.15104","volume":"47","author":"SM Ferrucci","year":"2022","unstructured":"Ferrucci SM, Buffon S, Marzano AV, Maronese CA (2022) Phenotypic switch from atopic dermatitis to psoriasis during treatment with Upadacitinib. Clin Exp Dermatol 47:986\u2013987. https:\/\/doi.org\/10.1111\/ced.15104","journal-title":"Clin Exp Dermatol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09129-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09129-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09129-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:36:10Z","timestamp":1769675770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09129-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9129"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09129-z","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this systematic review, as it is based on previously published studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4"}}